CoChat

Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial

Open access
Sattar, Naveed, Neeland, Ian J, Dahlqvist Leinhard, Olof, Fernández Landó, Laura, Bray, Ross, Linge, Jennifer, Rodriguez, Angel · 2025 · The Lancet Diabetes & Endocrinology

The DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index; 7 of the 9 sources its claims cite were checked for support.

Abstract

BACKGROUND Substantial weight reduction is often associated with loss of muscle mass. Tirzepatide has been associated with significant reductions in body weight in type 2 diabetes trials and a beneficial effect on body fat distribution in the SURPASS-3 MRI substudy. This post-hoc exploratory analysis studied the association of tirzepatide treatment with changes in thigh muscle volume, muscle volume Z score, and muscle fat infiltration, and aimed to contextualise the results using longitudinal MRI data from UK Biobank participants. METHODS SURPASS-3 was a randomised, open-label, parallel-group, phase 3 trial. The multicentre (45 sites) and multinational (eight countries) MRI substudy of SURPASS-3 enrolled insulin-naive adults (aged ≥18 years) with type 2 diabetes who were on treatment with metformin with or without a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, had an HbA1c of 7·0-10·5% (53-91 mmol/mol), a BMI of at least 25 kg/m2, and a fatty liver index of at least 60. Participants were randomly assigned (1:1:1:1) to receive subcutaneous injection once per week of tirzepatide (5, 10, or 15 mg), or subcutaneous injection once per day of titrated insulin degludec. Thigh muscle fat infiltration, muscle volume, and muscle volume Z score (invariant to sex, height, weight, and BMI) were quantified by MRI at baseline and week 52. In this post-hoc analysis, we assessed the differences between mean baseline and week 52 muscle composition values in the tirzepatide groups (poole…

Overview

CoChat Summary

TL;DR

In a post-hoc analysis of the SURPASS-3 MRI substudy, tirzepatide reduced thigh muscle fat infiltration and muscle volume/Z score at 52 weeks in adults with type 2 diabetes, alongside substantial weight loss. Muscle volume loss was similar to UK Biobank population-based estimates for weight change, but myosteatosis reduction was greater than expected.

Key findings

  • Among 246 participants with a valid week 52 MRI (tirzepatide 5 mg n=63; 10 mg n=60; 15 mg n=67; insulin degludec n=56), pooled tirzepatide significantly reduced muscle fat infiltration (mean change –0·36 percentage points [95% CI –0·48 to –0·25], p<0·0001), muscle volume (–0·64 L [–0·74 to –0·54], p<0·0001), and muscle volume Z score (–0·22 [–0·29 to –0·15], p<0·0001), with mean relative weight change –10·1% (–11·2 to –9·0, p<0·0001).
  • Insulin degludec modestly increased muscle volume (0·16 L [0·01 to 0·31], p=0·043) and bodyweight (3·3% [1·8 to 4·9], p=0·0001), with no significant change in muscle volume Z score (0·06 [–0·06 to 0·18], p=0·35) or muscle fat infiltration (0·03 percentage points [–0·09 to 0·14], p=0·62); all three pooled tirzepatide changes differed significantly from insulin degludec (p<0·01).
  • Versus UK Biobank population-based estimates (n=2942), pooled tirzepatide muscle volume change was similar (mean difference –0·04 L [–0·11 to 0·03], p=0·22), while muscle fat infiltration reduction was greater (–0·42 percentage points [–0·54 to –0·31], p<0·0001); tirzepatide 15 mg had a greater muscle volume Z score reduction than estimated (–0·18 [–0·29 to –0·07], p=0·0016).
  • Subgroup analyses found older participants (≥60 years) had a significantly larger decrease in muscle volume Z score with tirzepatide than younger participants; no significant differences in muscle composition changes were observed by sex, baseline muscle volume Z score, or baseline muscle fat infiltration categories.

Methods

  • Post-hoc exploratory analysis of the SURPASS-3 MRI substudy, a randomised, open-label, parallel-group phase 3 trial at 45 sites in eight countries. Participants were insulin-naive adults with type 2 diabetes on metformin with or without an SGLT-2 inhibitor, HbA1c 7·0–10·5%, BMI ≥25 kg/m², and fatty liver index ≥60, randomly assigned 1:1:1:1 to weekly tirzepatide 5, 10, or 15 mg or daily insulin degludec.
  • MRI at baseline and week 52 quantified thigh muscle fat infiltration, muscle volume, and muscle volume Z score. Analyses used modified intention to treat in participants with a valid week 52 MRI; paired t tests assessed within-group changes, and ANCOVA adjusted for baseline value, baseline HbA1c, SGLT-2 inhibitor use, and country compared pooled tirzepatide with insulin degludec.
  • Observed changes were compared with population-based estimates from multiple linear regression models fitted to longitudinal MRI data from 2,942 UK Biobank participants; missing values were handled by complete-case analysis, and R version 4.4.0 was used with p<0·05 defining significance.

Limitations

  • The paper describes this as a post-hoc exploratory analysis of an open-label trial, and the MRI substudy selected participants with fatty liver index ≥60 and a valid week 52 scan, which limits generalisability.
  • Complete-case analysis was used for missing values; only 206 of 246 included participants had complete muscle composition data at both baseline and week 52, which may introduce bias.
  • The UK Biobank comparison is observational and used only to contextualise expected weight-related muscle changes, not to establish causality; the provided text is truncated before any formal discussion/limitations section, so author-stated limitations may be incomplete here.

Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(25)00027-0

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

4 Valid · 0 Not valid · 1 Not checked · 42 Own results and interpretations

27 more claims

Create a free account to see all 47 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 13
  • It may state two separate claims as one. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. Linge, 2023, Two years of wasting with metabolic disorders—initial results on muscle composition from the longitudinal UK Biobank. The Liver Meeting: Boston, Massachusetts; Nov 10–14, 2023, Hepatology, 78, S1

Cited by

See all 131

Metadata

Authors
Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A.
Affiliations
  • British Heart Foundation (GB)
  • University Hospitals of Cleveland (US)
  • Eli Lilly (United States) (US)
  • Linköping University (SE)
Corresponding author
Sattar, Naveed
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2025-06
Volume
13
Issue
6
Pages
482-493
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4409986582
Cited by
131
References
38
Citations by year
2026: 93 · 2025: 38
FWCI
71.96
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
tirzepatide, type 2 diabetes, muscle composition, thigh muscle volume, muscle fat infiltration, insulin degludec, weight loss, body fat distribution, hepatic steatosis, metformin, SGLT2 inhibitors, insulin therapy
MeSH terms
Tirzepatide, Adult, Aged, Body Composition, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Magnetic Resonance Imaging, Male, Middle Aged, Muscle, Skeletal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(25)00027-0
The paper
Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(25)00027-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.